In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Little is known about the in vivo development of resistance to human immunodeficiency virus type 1 (HIV-1) CCR5 antagonists. We studied 29 subjects with virologic failure from a phase IIb study of the CCR5 antagonist vicriviroc (VCV) and identified one individual with HIV-1 subtype C who developed V...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Tsibris, Athe M. N., Sagar, Manish, Gulick, Roy M., Su, Zhaohui, Hughes, Michael, Greaves, Wayne, Subramanian, Mani, Flexner, Charles, Giguel, Françoise, Leopold, Kay E., Coakley, Eoin, Kuritzkes, Daniel R.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society for Microbiology (ASM) 2008
الموضوعات:
Vaccines and Antiviral Agents
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC2519584/
https://ncbi.nlm.nih.gov/pubmed/18495779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00444-08
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة